IBDEI1ZA ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33569,2)
 ;;=^5002607
 ;;^UTILITY(U,$J,358.3,33570,0)
 ;;=E10.59^^131^1672^4
 ;;^UTILITY(U,$J,358.3,33570,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33570,1,3,0)
 ;;=3^DM Type 1 w/ Circulatory Complications
 ;;^UTILITY(U,$J,358.3,33570,1,4,0)
 ;;=4^E10.59
 ;;^UTILITY(U,$J,358.3,33570,2)
 ;;=^5002612
 ;;^UTILITY(U,$J,358.3,33571,0)
 ;;=E10.618^^131^1672^5
 ;;^UTILITY(U,$J,358.3,33571,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33571,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Arthropathy
 ;;^UTILITY(U,$J,358.3,33571,1,4,0)
 ;;=4^E10.618
 ;;^UTILITY(U,$J,358.3,33571,2)
 ;;=^5002614
 ;;^UTILITY(U,$J,358.3,33572,0)
 ;;=E10.621^^131^1672^7
 ;;^UTILITY(U,$J,358.3,33572,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33572,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,33572,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,33572,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,33573,0)
 ;;=E10.622^^131^1672^11
 ;;^UTILITY(U,$J,358.3,33573,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33573,1,3,0)
 ;;=3^DM Type 1 w/ Skin Ulcer
 ;;^UTILITY(U,$J,358.3,33573,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,33573,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,33574,0)
 ;;=E10.65^^131^1672^10
 ;;^UTILITY(U,$J,358.3,33574,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33574,1,3,0)
 ;;=3^DM Type 1 w/ Hyperglycermia
 ;;^UTILITY(U,$J,358.3,33574,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,33574,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,33575,0)
 ;;=E10.39^^131^1672^9
 ;;^UTILITY(U,$J,358.3,33575,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33575,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Ophthalmic Complications NEC
 ;;^UTILITY(U,$J,358.3,33575,1,4,0)
 ;;=4^E10.39
 ;;^UTILITY(U,$J,358.3,33575,2)
 ;;=^5002603
 ;;^UTILITY(U,$J,358.3,33576,0)
 ;;=E66.3^^131^1672^45
 ;;^UTILITY(U,$J,358.3,33576,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33576,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,33576,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,33576,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,33577,0)
 ;;=E89.1^^131^1672^49
 ;;^UTILITY(U,$J,358.3,33577,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33577,1,3,0)
 ;;=3^Postprocedural Hypoinsulinemia
 ;;^UTILITY(U,$J,358.3,33577,1,4,0)
 ;;=4^E89.1
 ;;^UTILITY(U,$J,358.3,33577,2)
 ;;=^5003036
 ;;^UTILITY(U,$J,358.3,33578,0)
 ;;=H40.9^^131^1673^9
 ;;^UTILITY(U,$J,358.3,33578,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33578,1,3,0)
 ;;=3^Glaucoma,Unspec
 ;;^UTILITY(U,$J,358.3,33578,1,4,0)
 ;;=4^H40.9
 ;;^UTILITY(U,$J,358.3,33578,2)
 ;;=^5005931
 ;;^UTILITY(U,$J,358.3,33579,0)
 ;;=H26.9^^131^1673^5
 ;;^UTILITY(U,$J,358.3,33579,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33579,1,3,0)
 ;;=3^Cataract,Unspec
 ;;^UTILITY(U,$J,358.3,33579,1,4,0)
 ;;=4^H26.9
 ;;^UTILITY(U,$J,358.3,33579,2)
 ;;=^5005363
 ;;^UTILITY(U,$J,358.3,33580,0)
 ;;=H10.9^^131^1673^8
 ;;^UTILITY(U,$J,358.3,33580,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33580,1,3,0)
 ;;=3^Conjunctivitis,Unspec
 ;;^UTILITY(U,$J,358.3,33580,1,4,0)
 ;;=4^H10.9
 ;;^UTILITY(U,$J,358.3,33580,2)
 ;;=^5004716
 ;;^UTILITY(U,$J,358.3,33581,0)
 ;;=H11.32^^131^1673^6
 ;;^UTILITY(U,$J,358.3,33581,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33581,1,3,0)
 ;;=3^Conjunctival Hemorrhage,Left Eye
 ;;^UTILITY(U,$J,358.3,33581,1,4,0)
 ;;=4^H11.32
 ;;^UTILITY(U,$J,358.3,33581,2)
 ;;=^5004783
 ;;^UTILITY(U,$J,358.3,33582,0)
 ;;=H11.31^^131^1673^7
 ;;^UTILITY(U,$J,358.3,33582,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33582,1,3,0)
 ;;=3^Conjunctival Hemorrhage,Right Eye
 ;;^UTILITY(U,$J,358.3,33582,1,4,0)
 ;;=4^H11.31
 ;;^UTILITY(U,$J,358.3,33582,2)
 ;;=^5004782
